Aberdeen Group
THC icon

Aberdeen Group’s Tenet Healthcare THC Stock Holding History

Aberdeen Group’s Portfolio THC Stock Details THC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.52M Sell
18,820
-1,895
-9% -$348K ﹤0.01% 724
2026
Q1 		$3.91M Sell
20,715
-16,522
-44% -$3.48M 0.01% 715
2025
Q4 		$7.4M Hold
37,237
– – 0.01% 656
2025
Q3 		$7.49M Sell
37,237
-22,372
-38% -$3.97M 0.01% 649
2025
Q2 		$10.5M Sell
59,609
-38,620
-39% -$5.81M 0.02% 584
2025
Q1 		$13.2M Hold
98,229
– – 0.03% 497
2024
Q4 		$12.3M Buy
98,229
+22,066
+29% +$3.28M 0.02% 471
2024
Q3 		$12.7M Sell
76,163
-31,807
-29% -$4.81M 0.02% 471
2024
Q2 		$14.4M Sell
107,970
-22,100
-17% -$2.66M 0.03% 446
2024
Q1 		$13.7M Sell
130,070
-19,000
-13% -$1.71M 0.03% 496
2023
Q4 		$11.3M Buy
+149,070
New +$9.45M 0.02% 527
2022
Q1 		– Sell
-25,035
Closed -$2.04M – 1048
2021
Q4 		$2.04M Sell
25,035
-1,058
-4% -$77.3K ﹤0.01% 775
2021
Q3 		$1.79M Sell
26,093
-3,385
-11% -$240K ﹤0.01% 802
2021
Q2 		$1.98M Sell
29,478
-1,109
-4% -$68.8K ﹤0.01% 772
2021
Q1 		$1.59M Sell
30,587
-17,786
-37% -$899K ﹤0.01% 798
2020
Q4 		$1.93M Sell
48,373
-1,517
-3% -$49K ﹤0.01% 751
2020
Q3 		$1.22M Sell
49,890
-639
-1% -$16.3K ﹤0.01% 771
2020
Q2 		$915K Sell
50,529
-99
-0.2% -$1.95K ﹤0.01% 796
2020
Q1 		$729K Buy
50,628
+5,626
+13% +$161K ﹤0.01% 792
2019
Q4 		$1.71M Sell
45,002
-7,078
-14% -$212K ﹤0.01% 743
2019
Q3 		$1.15M Buy
52,080
+2,378
+5% +$50.7K ﹤0.01% 785
2019
Q2 		$1.03M Sell
49,702
-983
-2% -$22.7K ﹤0.01% 822
2019
Q1 		$1.46M Sell
50,685
-15,851
-24% -$391K ﹤0.01% 766
2018
Q4 		$1.17M Buy
66,536
+1,200
+2% +$29K ﹤0.01% 745
2018
Q3 		$1.86M Sell
65,336
-1,810
-3% -$59.8K ﹤0.01% 746
2018
Q2 		$2.25M Sell
67,146
-444
-0.7% -$13.8K ﹤0.01% 712
2018
Q1 		$1.64M Buy
67,590
+2,419
+4% +$48.2K ﹤0.01% 699
2017
Q4 		$988K Hold
65,171
– – ﹤0.01% 732
2017
Q3 		$1.07M Buy
+65,171
New +$1.11M ﹤0.01% 716

Other funds holding THC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Aberdeen Group's THC Position: Q2 2026 in Review

Aberdeen Group reduced its Tenet Healthcare (THC) stake by 9.1% in Q2 2026, selling an estimated $348K and leaving 18,820 shares worth $3.52M. The position accounts for ﹤0.01% of the portfolio, ranked #724.

Aberdeen Group first reported a position in THC in Q3 2017 and has held it in 29 quarters since. The position peaked at $14.4M in Q2 2024. 679 funds tracked by Wall St. Rank hold THC as of Q2 2026.

  • Aberdeen Group held 18,820 shares of Tenet Healthcare worth $3.52M as of Q2 2026.
  • Aberdeen Group sold 1,895 Tenet Healthcare shares in Q2 2026, an estimated $348K.
  • Tenet Healthcare made up ﹤0.01% of Aberdeen Group's portfolio in Q2 2026, its #724 holding.
  • Aberdeen Group first reported a position in Tenet Healthcare in Q3 2017 and has held it in 29 quarters since.
  • Aberdeen Group's Tenet Healthcare position peaked at $14.4M in Q2 2024.
  • 679 funds tracked by Wall St. Rank held Tenet Healthcare as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.